Catalyst Event

Eli Lilly and Co (LLY) · Other

From Akros SCHK HK-Global Quality Factor Index (ASHGQLT)

3/28/2026, 12:00:00 AM

OtherSentiment: Positive

Presented positive Phase 3b clinical trial data showing that the combination of its drugs Taltz and Zepbound was superior to Taltz alone for treating adults with active psoriatic arthritis and obesity. Analysts estimate a price impact of ≥1% due to positive clinical results, estimated.

Korean Translation

자사 약물인 탈츠(Taltz)와 젭바운드(Zepbound) 병용 요법이 활동성 건선성 관절염 및 비만 성인 환자 치료에 있어 탈츠 단독 요법보다 우수하다는 긍정적인 3b상 임상시험 데이터를 발표함. 긍정적인 임상 결과로 인해 분석가들은 1% 이상의 주가 영향을 예상함.

Related Recent Events

View Full Timeline